Teva and Neos settle over Cotempla patent dispute

Teva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over the Israeli firm’s generic version of Neos’ ADHD drug Cotempla XR-ODT (methylphenidate). Under the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT extended-release orally disintegrating tablets in the US under an Abbreviated New Drug Application (ANDA), beginning on 1 July 2026, or earlier under certain circumstances. In a statement, News said that the agreement resolves all ongoing litigation involving Cotempla XR-ODT and Teva’s ANDA.
“We are pleased to have reached this settlement and will continue to defend our innovative medicines against any challenge,” said Jerry McLaughlin, chief executive officer of Neos Therapeutics. Shares in Teva rose about 5% on the back of the news, while Neos shares fell 8%. Neos specializes in developing, manufacturing, and commercialising extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms. Other ADHD products in its portfolio include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Adzenys-ER (amphetamine) extended-release oral suspension.